Literature DB >> 14684737

Up-regulation of Bcl-2 homology 3 (BH3)-only proteins by E2F1 mediates apoptosis.

Tzippi Hershko1, Doron Ginsberg.   

Abstract

The E2F1 transcription factor is a critical downstream target of the tumor suppressor pRB. The retinoblastoma (RB) pathway is often inactivated in human tumors, resulting in deregulated E2F activity that can induce both proliferation and apoptosis. Bcl-2 homology 3 (BH3)-only proteins are pro-apoptotic members of the Bcl-2 protein family that trigger apoptosis in response to diverse stimuli. We show here that E2F1 up-regulates the expression of the pro-apoptotic BH3-only proteins PUMA, Noxa, Bim, and Hrk/DP5 through a direct transcriptional mechanism. Expression of the E7 protein of HPV16, which disrupts RB/E2F complexes, also up-regulates the expression of these four BH3-only proteins, implicating endogenous E2F in this phenomenon. Indeed, endogenous E2F1 binds the promoters of these four genes. Furthermore, inhibition of E2F1-induced expression of either Noxa or PUMA results in a significant reduction in E2F1-induced apoptosis, indicating that increased Noxa and PUMA levels mediate this E2F1-induced apoptosis. Importantly, inhibition of E2F activity abolishes DNA damage-induced elevation of PUMA levels, implicating E2F in the physiological regulation of PUMA expression. These data provide a novel direct link between E2F and the apoptotic machinery and may explain the increased sensitivity of cells with a defective RB/E2F pathway to chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14684737     DOI: 10.1074/jbc.M312866200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  126 in total

Review 1.  BH3-only proteins in apoptosis at a glance.

Authors:  Lina Happo; Andreas Strasser; Suzanne Cory
Journal:  J Cell Sci       Date:  2012-03-01       Impact factor: 5.285

Review 2.  Role of cell cycle re-entry in neurons: a common apoptotic mechanism of neuronal cell death.

Authors:  Jaume Folch; Felix Junyent; Ester Verdaguer; Carme Auladell; Javier G Pizarro; Carlos Beas-Zarate; Mercè Pallàs; Antoni Camins
Journal:  Neurotox Res       Date:  2011-10-01       Impact factor: 3.911

3.  The novel tryptamine derivative JNJ-26854165 induces wild-type p53- and E2F1-mediated apoptosis in acute myeloid and lymphoid leukemias.

Authors:  Kensuke Kojima; Jared K Burks; Janine Arts; Michael Andreeff
Journal:  Mol Cancer Ther       Date:  2010-08-24       Impact factor: 6.261

Review 4.  Cell Death Signaling.

Authors:  Douglas R Green; Fabien Llambi
Journal:  Cold Spring Harb Perspect Biol       Date:  2015-12-01       Impact factor: 10.005

5.  Hzf, a p53-responsive gene, regulates maintenance of the G2 phase checkpoint induced by DNA damage.

Authors:  Masataka Sugimoto; Adam Gromley; Charles J Sherr
Journal:  Mol Cell Biol       Date:  2006-01       Impact factor: 4.272

6.  BNIP3 is an RB/E2F target gene required for hypoxia-induced autophagy.

Authors:  Kristin Tracy; Benjamin C Dibling; Benjamin T Spike; James R Knabb; Paul Schumacker; Kay F Macleod
Journal:  Mol Cell Biol       Date:  2007-06-18       Impact factor: 4.272

7.  p16(INK4a) protects against dysfunctional telomere-induced ATR-dependent DNA damage responses.

Authors:  Yang Wang; Norman Sharpless; Sandy Chang
Journal:  J Clin Invest       Date:  2013-09-16       Impact factor: 14.808

8.  Functional interplay between E2F1 and chemotherapeutic drugs defines immediate E2F1 target genes crucial for cancer cell death.

Authors:  David Engelmann; Susanne Knoll; Daniel Ewerth; Marc Steder; Anja Stoll; Brigitte M Pützer
Journal:  Cell Mol Life Sci       Date:  2009-12-15       Impact factor: 9.261

Review 9.  p53 and E2f: partners in life and death.

Authors:  Shirley Polager; Doron Ginsberg
Journal:  Nat Rev Cancer       Date:  2009-10       Impact factor: 60.716

10.  Downregulation of Noxa by RAF/MEK inhibition counteracts cell death response in mutant B-RAF melanoma cells.

Authors:  Kevin J Basile; Andrew E Aplin
Journal:  Am J Cancer Res       Date:  2012-11-20       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.